Regulus Therapeutics Inc (NASDAQ:RGLS)
| 0.1999 Delayed Data As of Jan 24 |  -0.0241 / -10.76%Today’s Change | 0.19 Today|||52-Week Range 2.32 | -36.54% Year-to-Date |
Latest RGLS News | Press Releases
| Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ... Jan 19 / GuruFocus News - Paid Partner Content |
Today’s Trading
| Previous close | 0.22 |
| Today’s open | 0.22 |
| Day’s range | 0.19 - 0.22 |
| Volume | 256,264 |
| Average volume (3 months) | 1,910,937 |
| Market cap | $19.5M |
Data as of 3:58pm ET, 01/24/2022
Growth & Valuation
| Earnings growth (last year) | +58.25% |
| Earnings growth (this year) | +25.56% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +46.46% |
| P/E ratio | NM |
| Price/Sales | 4.72 |
| Price/Book | 0.58 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| IMRNImmuron Ltd | +0.11 | +3.12% |
| ---- | ||
| KTRAKintara Therapeutics... | -0.02 | -6.30% |
| ---- |
Data as of 4:03pm ET, 01/24/2022
Financials
| Next reporting date | March 9, 2022 |
| EPS forecast (this quarter) | -$0.08 |
| Annual revenue (last year) | $10.0M |
| Annual profit (last year) | -$15.7M |
| Net profit margin | -157.21% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
